Faculty Summaries
Gregory P Adams, PhD
Gregory P Adams, PhD
Associate Professor
  • Associate Professor, Department of Microbiology and Immunology, Temple University School of Medicine
  • Co-Leader, Developmental Therapeutics
Gregory.Adams@fccc.edu
Office Phone: 215-728-3890
Fax: 215-728-2741
Office: W364

Publications

  • Rudnick SI, Adams GP. Affinity and avidity in antibody-based tumor targeting. Cancer Biother Radiopharm. 2009 Apr;24(2):155-61.
  • Yang L, Mao H, Wang YA, Cao Z, Peng X, Wang, Hongwei Duan, Chunchun Ni, Qingan Yuan, Adams G, Smith MQ, Wood WC, Gao X, Nie S. Single Chain Epidermal Growth Factor Receptor Antibody Conjugated Nanoparticles for in vivo Tumor Targeting and Imaging. Small 5, No. 2:235–43. 2009
  • Loo L, Robinson MK, Adams GP. Antibody engineering principles and applications. Cancer J. 2008 May-Jun;14(3):149-53.
  • Adams GP. Enhancing the efficiency of targeted radionuclide treatment. in Targeted Radionuclide Tumor Therapy - Biological aspects. (2008) Stigbrand T, Adams GP, and Carlsson J (Eds). Springer, New York, NY pp 321-328.
  • Adams GP. Antibody fragments produced by recombinant and proteolytic methods. in Targeted Radionuclide Tumor Therapy - Biological aspects. (2008) Stigbrand T, Adams GP, and Carlsson J (Eds). Springer, New York, NY pp 77-88.
  • Adams GP. Targeted Radionuclide Tumor Therapy - Biological aspects. (2008) Stigbrand T, Adams GP, and Carlsson J (Eds). Springer, New York, NY.
  • Robinson MK, Hodge KM, Horak E, Sundberg AL, Russeva M, Shaller CC, von Mehren M, Shchaveleva I, Simmons HH, Marks JD, Adams GP. Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro. Br J Cancer. 2008 Nov 4;99(9):1415-25.
  • Sui JH, Aird DR, Tamin A, Murakami A, Yan MY, Yammanuru A, Jing HQ, Kan B, Liu X, Zhu Q, Yuan QA, Adams GP, Bellini WJ, Xu JG, Anderson LJ, Marasco WA. Broadening of Neutralization Activity to Directly Block a Dominant Antibody-Driven SARS-Coronavirus Evolution Pathway. PLoS Pathogens. 2008 Nov;4(11).
  • Capobianco JA, Shih WY, Yuan QA, Adams GP, Shih WH. Label-free, all-electrical, in situ human epidermal growth receptor 2 detection. Rev Sci Instrum. 2008 Jul;79(7):076101.
  • Robinson MK, Shaller C, Garmestani K, Plascjak PS, Hodge KM, Yuan QA, Marks JD, Waldmann TA, Brechbiel MW, Adams GP. Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the alpha-emitting radioisotope astatine-211 conjugated to anti-HER2/neu diabodies. Clin Cancer Res. 2008 Feb 1;14(3):875-82.
  • Yuan QA, Robinson MK, Simmons HH, Russeva M, Adams GP. Isolation of anti-MISIIR scFv molecules from a phage display library by cell sorter biopanning. Cancer Immunol Immunother. 2008;14:875-82.
  • Zhou Y, Daryl C, Zou H, Hayes ME, Adams GP, Kirpotin DB, Marks JD. Impact of single-chain fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells. J Mol Biol. 2007 Aug;371(4):934-47.
  • Friedman M, Nordberg E, Hoiden-Guthenberg I, Brisimar H, Adams GP, Nilsson FY, Carlss J, Stahl S. Phage display selection of Affibody molecules with specific binding to the extracellular domain of the epidermal growth factor receptor. Protein Engineering Design & Selection. 2007 Apr;20(4):189-99.
  • Yuan Q, Simmons HH, Robinson MK, Russeva M, Marasco WA, Adams GP. Development of engineered antibodies specific for the Muellerian inhibiting substance type II receptor: a promising candidate for targeted therapy of ovarian cancer. Molecular Cancer Therapeutics. 2006;5(8):2096-105.
  • Steffen AC, Orlova A, Wikman M, Nilsson FY, Stahl S, Adams GP, Tolmachev V, Carlsson J. Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2006 Jun;33(6):631-8.
  • Adams GP, Tai M, McCartney JE, Marks JD, Stafford WF, Houston LL, Huston JS, Weiner LM. Avidity-Mediated Enhancement of In vivo Tumor Targeting by Single-Chain Fv Dimers. Clin Cancer Res. 2006;12(5):1599-605.
  • Horak E, Heitner T, Robinson MK, Simmons HH, Garrison J, Russeva M, Furmanova P, Lou J, Zhou Y, Yuan Q, Weiner LM, Adams GP, Marks JD. Isolation of scFvs to In Vitro Produced Extracellular Domains of EGFR Family Members. Cancer Biotherapy & Radiopharmaceuticals. 2005;20(6):603-13.
  • Cheng JD, Adams GP, Robinson MK, Weiner LM. Monoclonal Antibodies: in Cancer: Principles and Practice of Oncology, 7th Edition, (2005) VT DeVita, S Hellman, SA Rosenberg (eds). Lippincott Williams & Wilkins, Philadelphia, PA, pp. 445-456.
  • Steffen AC, Wikman M, Tolmachev V, Adams GP, Nilsson FY, Stahl S, Carlsson J. In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnostics. Cancer Biotherapy and Radiopharmaceuticals. 2005 Jun;20(3):239-48.
  • Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol. 2005 Sep;23(9):1147-57.
  • Robinson MK, Doss M, Shaller C, Narayanan D, Marks JD, Adler LP, Trotter DE, Adams GP. Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. Cancer Res. 2005;65(4):1471-8.
  • Adams GP, Russeva MG. Radioimmunotherapy with Engineered Antibodies. Expert Opinion in Biological Therapy. 2004;4:217-231.
  • Robinson MK, Weiner LM, Adams GP. Improving monoclonal antibodies for cancer therapy. Drug Development Research. 2004 Mar;61(3):172-87.
  • Adams GP, Shaller CC, Dadachova E, Simmons HH, Horak EM, Tesfaye A, Klein-Szanto AJ, Marks JD, Brechbiel MW, Weiner LM. A single treatment of yttrium-90-labeled CHX-A"-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice.[see comment]. Cancer Res. 2004 Sep 1;64(17):6200-6.
  • Chmielewski M, Hombach A, Heuser C, Adams GP, Abken H. T cell activation by antibody-like immunoreceptors: Increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity. J Immunol. 2004 Dec 15;173(12):7647-53.
  • Wikman M, Steffen AC, Gunneriusson E, Tolmachev V, Adams GP, Carlsson J, Stahl S. Selection and characterization of HER2/neu-binding affibody ligands. Protein Engineering Design & Selection. 2004 May;17(5):455-62.
  • Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, Alpaugh RK, Marks JD, Weiner LM. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res. 2001 Jun 15;61(12):4750-5.
  • Adams GP, Schier R, McCall AM, Crawford RS, Wolf EJ, Weiner LM, Marks JD. Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. Br J Cancer. 1998 May;77(9):1405-12.
Top